Figure 2
From: TERT promoter mutations contribute to subset prognostication of lower-grade gliomas
Correlations between clinicopathological and molecular variables of lower-grade gliomas. Clinical and molecular data of 237 lower-grade gliomas (a). TERT promoter mutation is associated with oligodendroglial histology (P<0.001, χ2-test) (b). TERT promoter mutation was not associated with IDH mutation in the whole cohort (P=0.185, χ2-test) (c). TERT promoter mutation was inversely associated with IDH mutation among astrocytic tumors with intact 1p/19q (P=0.008, χ2-test) (d), co-occurred with IDH mutation among oligodendroglial tumors (P=0.001, Fisher’s exact test) (e), and co-occurred with 1p/19q codeletion in the whole cohort (P<0.001, χ2-test) (f). Patients with IDH wild-type-TERT-mutated gliomas are older than those with IDH wild-type-TERT wild-type tumors, IDH-mutated-TERT-wild-type tumors and trended to be older than IDH-mutated-TERT-mutated tumors, (One-way ANOVA) (g). Mut, mutated; wt, wild type.
